基于枝化多肽的多功能药物递送系统用于肿瘤细胞核的精准靶向治疗

为了改善在肿瘤治疗过程中,药物载体靶向性差和药物靶点定位效率低等不足,设计了一种能精准靶向肿瘤细胞核,将药物高效递送至作用靶点的多功能纳米载药体系.利用具有细胞核定位能力的两亲性枝化多肽包载化疗药物阿霉素(DOX)形成载药纳米胶束DD,并通过静电作用将具有肿瘤靶向功能的透明质酸(HA)包覆在DD表面,得到具有靶向肿瘤细胞核能力的纳米药物HDD.HA的存在赋予了HDD对肿瘤的靶向功能和电荷屏蔽能力,可增加体系的稳定性,延长其血液循环时间,降低正常组织和细胞对HDD的非特异性摄取,实现其在肿瘤部位的特异性富集和肿瘤细胞的高效摄取.进入肿瘤细胞后,HA层的降解有利于纳米胶束DD在多肽的核定位作用下精准、快速地将DOX递送至细胞核,最终实现高效的肿瘤抑制效果.     

刺激响应脂质体及其在控制释药中的应用

刺激响应型纳米药物递送系统是一种功能性纳米给药系统.刺激响应脂质体不仅提供定位化学治疗,而且还具有控制释放药物的潜能,因此对于实施控制治疗肿瘤具有重要意义.当脂质体在特殊环境(包括热、光、磁和p H等)刺激下,可通过载体微观结构发生变化释放药物.刺激响应脂质体的优势是可减少或避免药物过早释放,提高靶向部位的释药效率.本文介绍了刺激响应脂质体的结构、特性和功能,分别综述了热、光、磁、p H刺激响应和p H-温度双刺激响应脂质体的特性,并讨论了刺激释药的机制.     

基于肿瘤微环境响应的DNA纳米结构递药系统

DNA分子由于其独特的生物相容性和可编程性,在增强药物靶向性和降低药物毒性方面展现了独特的优势和巨大的潜力。随着人们对肿瘤微环境研究的深入和环境响应性的DNA触发器的研制,近些年已报道了许多基于肿瘤微环境响应的DNA纳米结构递药系统,这些DNA纳米结构递药系统结合了纳米运载工具良好的生物分布和药代动力学特性,以及小型药物载体的快速扩散和渗透特性。通过靶向广泛的肿瘤栖息地而不是肿瘤特异性受体,该策略有可能克服肿瘤异质性问题,并可用于设计诊断和治疗多种实体肿瘤的纳米颗粒。在体内能够稳定地转运,在肿瘤组织独特的微环境刺激下释放药物,能有效地控制药物释放部位和释放速度,极大地降低了肿瘤治疗的毒副作用。本文主要从pH响应型、GSH响应型、ATP响应型、酶响应型、抗原响应型五个方面,综述了基于肿瘤微环境响应的DNA纳米结构递药系统的最新研究进展,分类介绍了这些DNA纳米载体的设计策略和响应释放机制,此外,还重点介绍了该领域面临的前景和挑战。     

功能多肽在肿瘤治疗中的应用及研究进展

多肽具有生物相容性好,功能多样化,生物体内响应性高及合成修饰方法简单易行等优点,已被广泛用于构建靶向药物传递系统。以具有靶向功能和刺激响应性的多肽为基础构建的药物传递系统,能够将药物定向地运送到肿瘤区域。药物传递系统到达肿瘤组织后,在肿瘤组织特殊微环境或外源刺激下,实现药物的精准释放。这种具有特异性肿瘤靶向和刺激响应型的多肽载体可以最大程度地提高药物的抗肿瘤效果,降低药物的毒副作用。本文简要介绍了常用的靶向多肽和刺激响应型多肽,并讨论了基于功能型多肽的药物载体在肿瘤治疗方面的应用。     

生物还原敏感可降解聚合物纳米载体的构建与应用

生物可降解聚合物纳米载体具有较长的体内循环时间、能靶向并富集到肿瘤组织、降低毒副作用、增加药物利用率以及在体内可降解等优越性能,已成为实现肿瘤靶向治疗最有前景的载体系统之一。但是,临床试验结果表明,聚合物纳米药物的治疗效果与人们的预期相差甚远,其中一个重要原因是纳米药物在靶点处药物释放少且缓慢。因此,开发智能型纳米载体使其在到达靶点后即迅速释放包裹的药物成为近年的研究热点。肿瘤组织,尤其是肿瘤细胞内的谷胱甘肽(glutathione,GSH)浓度较高(2~10mM),大约是体液和细胞外基质的100~1000倍(2~10μM)。基于肿瘤独特的还原势能,人们构建了各种不同类型的还原敏感聚合物纳米载体,实现抗癌药物在肿瘤组织和肿瘤细胞内的快速高效释放。生物还原敏感聚合物纳米载体具有以下特点:(1)在生理条件下稳定;(2)对肿瘤细胞内还原环境响应快,触发药物快速释放;(3)无需任何外在刺激装置,简单方便。本文将结合我们课题组的工作介绍各种还原敏感可降解聚合物纳米载体的构建和应用,主要包括还原敏感生物可降解聚合物胶束、囊泡、纳米凝胶等。     

肿瘤微环境响应药物递送系统的设计

化学药物治疗(化疗)是目前临床上治疗肿瘤最有效的方法之一,但传统的给药方式导致药物对肿瘤的靶向性差、药物利用率低。在杀伤肿瘤细胞的同时,化疗药物对人体正常细胞也有很大的损伤,因此在化疗过程中通常伴随着严重的副作用,例如恶心、呕吐以及脱发等。随着肿瘤学和纳米材料的迅速发展,多种纳米药物载体被应用于肿瘤的治疗。纳米药物载体具有提高药物利用率、降低药物的毒副作用等诸多优势,已成为药物递送领域的研究热点。其中,肿瘤微环境响应纳米药物载体在实现肿瘤部位药物的可控释放、载体保护壳的脱除以及肿瘤靶向等方面表现出优异的性能。本文讨论了基于肿瘤微环境的异常生化指标构建肿瘤微环境响应载体的常用策略,并总结了近年来肿瘤微环境响应纳米药物载体用于肿瘤治疗的研究进展,旨在为设计与制备高性能纳米药物载体提供参考。     

透明质酸修饰的介孔二氧化硅包覆金纳米棒的制备及在肿瘤化疗-热疗联合治疗中的应用

通过在包覆了金纳米棒的介孔硅表面修饰生物相容性的透明质酸, 得到了具有肿瘤靶向性的多功能药物载体. 实验结果表明, 透明质酸可以通过酰胺键修饰在介孔硅表面, 所得药物载体可在透明质酸酶作用下实现选择性释放. 该体系在近红外区域具有较高的吸收, 可以在近红外光照射下实现光热转换. 细胞实验结果表明, 该多功能药物载体可以有效靶向CD44过量表达的乳腺癌细胞, 通过CD44介导的内吞富集在肿瘤内部, 结合化学药物治疗和光热治疗, 显示出更高的肿瘤细胞凋亡效率.     

一种新型CO_2响应型肿瘤靶向药物传递载体

将透明质酸(HA)依次接枝1,12-二氨基十二烷和N,N-二甲基乙酰胺二甲缩醛(DADA),构建得到CO_2刺激响应的透明质酸-脒基(HA-ami)。为了考察其结构、CO_2刺激响应性、细胞水平作为药物载体的可行性和肿瘤靶向性,进行了结构表征、CO_2刺激响应性表征、细胞摄取、细胞毒性和体内的组织分布实验。结果表明:HA-ami成功构建,并具有一定的CO_2刺激响应性,可携带模型药物摄取进入人乳腺癌细胞(MCF-7),而且没有出现明显的细胞毒性,具有体内肿瘤靶向性。     

多肽介导的肿瘤靶向纳米递药系统

肿瘤靶向纳米递药系统是指利用肿瘤组织特殊的生理病理特点,由纳米载体包载肿瘤诊疗药物构建而成的对肿瘤组织具有靶向定位功能的药物递送系统。多肽介导的肿瘤靶向纳米递药系统是肿瘤靶向递药领域较新的一个研究方向,本文综述了该研究方向的四个重要发展历程——单功能靶向、双功能靶向、肿瘤穿透和环境响应型靶向纳米递药系统,并介绍了各类递药系统的设计原理和典型研究案例。此外,对目前多肽介导的纳米递药系统存在的优势与不足进行了分析。最后,针对当前主动靶向肿瘤递药系统存在的研究困境,提出了一种新型肿瘤靶向递药策略——"系统性靶向"策略。随着相关学科和多学科交叉的发展,多肽介导的肿瘤靶向纳米递药系统将在肿瘤治疗中扮演更为重要的角色。     

pH/酶/光热多重响应的金纳米笼/透明质酸核壳结构纳米载体的制备与性能

以金纳米笼(AuNC)为核, 巯基化改性的透明质酸(LC-HA)为壳, 盐酸阿霉素(DOX)为药物模型, 通过简单的一锅法制备了核壳结构载药纳米粒子DOX@AuNC@HA(DAH). 金纳米笼为药物装载提供容器且赋予载体光热性能, 改性的透明质酸对金纳米笼进行包封并提供pH/酶响应及靶向介导功能. 对DAH的结构进行了表征, 并进行了载药、 控释性能以及细胞摄取和细胞毒性的研究. 结果表明, 核壳结构纳米微粒DAH具有较高的载药能力, 在激光源的照射下具有较好的循环稳定性和较高的光热转换率. 在pH=7.4的磷酸盐缓冲液中, DAH具有较高的稳定性, 20 h的药物泄露率低于20%; 而在酸性环境、 透明质酸酶(HAase)及光热作用下, DAH均能较快地释放出装载的药物, 展现出较好的刺激响应性. 此外, DAH能够更多地被肿瘤细胞摄取, 表现出一定的靶向性; 当化疗与光热疗法共同作用时, 肿瘤细胞的活性大大减弱, 展现出了联合疗法的优势及潜力.     

基于透明质酸构筑的药物递送载体及其应用

传统纳米药物控释载体主要通过细胞胞吞作用实现药物递送,其主要过程为被动靶向机制,因此会影响纳米载体在肿瘤组织的富集和治疗效果。近年来生物大分子透明质酸因其优异的水溶性、生物相容性、可降解性和肿瘤靶向性备受科研工作者青睐,已被广泛用于药物控释载体的构筑中,并成为靶向肿瘤治疗纳米载体领域的研究热点。本文根据透明质酸基纳米载体治疗机制的不同,从透明质酸基纳米载体在化疗、光热治疗、光动力治疗以及联合治疗的应用方面对其性能进行了总结和评述,并在此基础上展望了未来透明质酸基纳米治疗载体的研究方向和发展趋势。     

Two-dimensional LDH nanodisks modified with hyaluronidase enable enhanced tumor penetration and augmented chemotherapy

The condensed tumor extracellular matrix(ECM) consisting of cross-linked hyaluronic acid(HA) is one of the key factors that result in the aberrant tumor microenvironment and severely impair drug delivery and tumor penetration. Herein, we report a simple design of a hyaluronidase(HAase)-modified layered double hydroxide(LDH) nanoplatform loaded with anticancer drug doxorubicin(DOX) for enhanced tumor penetration and augmented chemotherapy. In our approach, LDH nanodisks were synthesized via a co-precipitation method, modified with HAase by electrostatic attraction, and finally physically loaded with DOX. The formulated DOX/LDH-HAase complexes show a high DOX loading percentage of 34.2% with good colloidal stability, retain 86.1% of the enzyme activity, and release DOX in a pH-responsive manner having a faster release rate under slightly acidic tumor microenvironment than that under a physiological condition. With the catalytic activity of HAase to digest the HA nearby the cancer cells, the developed DOX/LDH-HAase complexes enable more significant uptake by cancer cells and penetration in 3-dimensional tumor spheroids than enzyme-free DOX/LDH complexes, thus displaying much better antitumor efficacy in vitro than the latter. The more significant tumor penetration and inhibition of the DOX/LDH-HAase complexes than that of the DOX/LDH complexes was further demonstrated by in vivo tumor imaging and therapeutic activity assessments. Our study suggests a unique nanomedicine platform combined with both anticancer drug and enzyme for improved tumor penetration and chemotherapy, which is promising for effective chemotherapy of different types of stroma-rich tumors.     

A facile approach to construct hyaluronic acid shielding polyplexes with improved stability and reduced cytotoxicity

A facile approach for polymer gene carriers was used to construct hyaluronic acid (HA) shielding polyplexes due to the electrostatic interaction. By adding HA to PEI/DNA complexes, the ξ-potential of ternary polyplexes was changed from positive to negative. Spherical particles with diameter about 250nm were observed. Ethidium bromide exclusion assay indicated that the electrostatic complexation was loosened after addition of HA. However, DNA disassembly did not occur. The proper reason was that the intensity of negative charges was not strong enough to release DNA from the complexes in our experiment. The stability of PEI/DNA/HA polyplexes in physiological condition was improved and the cytotoxicity was reduced. Comparing with PEI/DNA polyplexes, the uptake and transfection efficiency of HA shielding polyplexes was lower for HEK293T cells probably due to the reduced adsorptive endocytosis, whereas it was higher for HepG2 cells due to HA receptor mediated endocytosis. This facile approach to constructing HA shielding polyplexes might have great potential application in non-viral gene delivery research and tumor therapy.     

Theranostic hyaluronic acid prodrug micelles with aggregation-induced emission characteristics for targeted drug delivery

Theranostic hyaluronic acid (HA) prodrug micelles with pH-responsive drug release and aggregation-induced emission (AIE) properties were prepared by chemical graft of biomimetic phosphorylcholine (PC), anticancer drug doxorubicin (DOX) and AIE fluorogen tetraphenylene (TPE) to the HA backbone. DOX was conjugated to the HA backbone by a hydrazone bond which can be hydrolyzed under acidic environment and result in pH-triggered smart release of DOX. The TPE units with typical AIE characteristics were applied for real time drug tracking in cancer cells. The HA-based prodrugs could self-assemble into micelles in aqueous solution as confirmed by the dynamic light scattering (DLS) and transmission electron microscopy (TEM). The intracellular distribution of HA prodrug micelles could be clearly observed by fluorescence microscopy based on the strong fluorescence of TPE. Moreover, after treated with the micelles, stronger fluorescence of TPE in CD44 overexpressed MDA-MB-231 cancer cells was observed, compared to the CD44 negative cell line, NIH3T3 cells, suggesting efficient cell uptake of HA prodrug micelles by receptor-mediated endocytosis. The cell viability results indicated that the prodrug micelles could inhibit the proliferation of the cancer cells effectively. Such pH-triggered theranostic drug delivery system with AIE features can provide a new platform for targeted and image-guided cancer therapy.     

Bioresponsive Hyaluronic Acid‐Capped Mesoporous Silica Nanoparticles for Targeted Drug Delivery

In this paper, we present a facile strategy to synthesize hyaluronic acid (HA) conjugated mesoporous silica nanoparticles (MSP) for targeted enzyme responsive drug delivery, in which the anchored HA polysaccharides not only act as capping agents but also as targeting ligands without the need of additional modification. The nanoconjugates possess many attractive features including chemical simplicity, high colloidal stability, good biocompatibility, cell‐targeting ability, and precise cargo release, making them promising agents for biomedical applications. As a proof‐of‐concept demonstration, the nanoconjugates are shown to release cargoes from the interior pores of MSPs upon HA degradation in response to hyaluronidase‐1 (Hyal‐1). Moreover, after receptor‐mediated endocytosis into cancer cells, the anchored HA was degraded into small fragments, facilitating the release of drugs to kill the cancer cells. Overall, we envision that this system might open the door to a new generation of carrier system for site‐selective, controlled‐release delivery of anticancer drugs.     

Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates

Paclitaxel (1a), a well known antitumor agent adopted mainly for the treatment of breast and ovarian cancer, suffers from significant disadvantages such as low solubility, certain toxicity and specific drug-resistance of some tumor cells. To overcome these problems extensive research has been carried out. Among the various proposed strategies, the conjugation of paclitaxel (1a) to a biocompatible polymer, such as hyaluronic acid (HA, 2), has also been considered. Coupling a bioactive compound to a biocompatible polymer offers, in general, many advantages such as better drug solubilization, better stabilization, specific localization and controlled release. Hereafter the design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates are reviewed. An overview of HA-paclitaxel combinations is also given.     

A pH‐Responsive Hydrogel Based on a Tumor‐Targeting Mesoporous Silica Nanocomposite for Sustained Cancer Labeling and Therapy

A facile strategy is presented to synthesize hyaluronic acid (HA) and a fluorescein isothiocyanate (FITC)‐conjugated mesoporous silica nanocomposite (MSN) with multiple functions of fluorescence, tumor‐cell targeting, pH‐triggered gelation, and enzyme‐responsive drug release. This injectable nanocomposite is able to indicate the entire tumor location and provides a microenvironment with rich anticancer drugs in and around tumor tissue for a long time, to avoid recrudescence. In this design, the mesoporous silica serves as the drug container, the FITC serves as a fluorescent probe, and the anchored HA plays multiple roles as drug‐release cap, tumor‐targeting points, and responsive gel matrix. Owing to the specific affinity between the HA on MSNs and the CD44 antigen over‐expressed on tumor cells, the MSNs can selectively attach to tumor cells. The nanocomposites then exploit the pH‐responsive interactions (hydrogen bonds) among the HA to self‐assemble in situ into a hydrogel around the tumor tissue. The resulting hydrogel gradually releases its payload (doxorubicin, anticancer drugs)‐loaded MSNs upon HA degradation in the presence of hyaluronidase‐1 (Hyal‐1), followed by endocytosis and intracellular drug release. All these properties have distinct benefits for tumor treatment, demonstrating that this device is a promising candidate for oncotherapy applications.

     

透明质酸的改性及在生物医用材料领域的应用研究

透明质酸(HA)是人体内最为常见的一种粘多糖,具有优良的生物相容性和可降解性,可广泛应用于药物输送、皮肤填充材料、组织工程、药物载体和3D仿生学等方面,是当前生物医用材料领域的研究热点之一。HA具有独特的结构使其显示出特定的物理化学性质,可通过物理或化学方法修饰,赋予其新功能和新应用。本文从HA的分子结构出发,重点综述了HA的官能团羧基、羟基和乙酰胺基的化学改性和物理改性,主要包括羧基的酰胺化反应和酯化反应,羟基与环氧化物的开环反应、与有机硫化物的反应、酯化反应、与卤化物的反应和氧化反应,以及HA脱乙酰基反应;介绍了HA在生物医用材料领域的应用,并对其前景进行展望。     

Formation of hyaluronic acid–ellagic acid microfiber hybrid hydrogels and their applications

Microfiber assemblies prepared from ellagic acid (EA) were functionalized with histidine (His) and dispersed in hyaluronic acid (HA) hydrogel microstructures. Swelling studies indicated that the hybrids had a relatively lower water uptake compared to HA and was pH dependent. The percentage swelling ratio for EA–His–HA hybrids was 48 % when 0.04 mg/mL of HA was incorporated and increased to 70 % when 1.2 mg/mL HA was integrated. Release studies using the dye crystal violet (CV) as a model drug showed that the rates were concentration-dependent. Further the hybrids were found to be thermally stable compared to HA. Cellular toxicity assays performed with normal rat kidney (NRK) cells indicated biocompatibility and adherence of the hybrids to the cells. Thus, we have developed a new family of hybrid hydrogels which readily formed on the EA–His functionalized microfibers and may have potential applications in drug delivery or tissue regeneration applications.